-$0.79 EPS Expected for Achaogen Inc (AKAO) This Quarter
Equities analysts expect Achaogen Inc (NASDAQ:AKAO) to report ($0.79) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Achaogen’s earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.99). Achaogen reported earnings of ($1.04) per share in the same quarter last year, which indicates a positive year over year growth rate of 24%. The firm is expected to announce its next earnings report on Tuesday, March 13th.
On average, analysts expect that Achaogen will report full year earnings of ($3.06) per share for the current financial year, with EPS estimates ranging from ($3.16) to ($2.92). For the next year, analysts expect that the company will report earnings of ($3.21) per share, with EPS estimates ranging from ($3.73) to ($2.78). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Achaogen.
Achaogen (NASDAQ:AKAO) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.13). The company had revenue of $0.58 million for the quarter, compared to analyst estimates of $2.09 million. Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. Achaogen’s quarterly revenue was down 96.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.41) earnings per share.
Achaogen (AKAO) opened at $11.54 on Friday. The stock has a market capitalization of $489.22, a PE ratio of -3.43 and a beta of 1.35. Achaogen has a 12-month low of $10.24 and a 12-month high of $27.79. The company has a current ratio of 6.99, a quick ratio of 6.99 and a debt-to-equity ratio of 0.08.
In other Achaogen news, major shareholder Robert W. Duggan acquired 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was acquired at an average cost of $10.89 per share, for a total transaction of $163,350.00. Following the transaction, the insider now owns 5,617,752 shares of the company’s stock, valued at $61,177,319.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Robert W. Duggan acquired 50,000 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was acquired at an average price of $11.51 per share, with a total value of $575,500.00. Following the completion of the transaction, the insider now directly owns 5,617,752 shares in the company, valued at approximately $64,660,325.52. The disclosure for this purchase can be found here. Insiders purchased a total of 160,012 shares of company stock valued at $1,796,334 over the last quarter. 8.36% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc acquired a new position in shares of Achaogen in the 2nd quarter valued at approximately $168,000. Ardsley Advisory Partners bought a new stake in Achaogen in the 2nd quarter valued at approximately $217,000. JPMorgan Chase & Co. lifted its stake in Achaogen by 691.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 9,677 shares in the last quarter. California Public Employees Retirement System bought a new stake in Achaogen in the 2nd quarter valued at approximately $243,000. Finally, Voya Investment Management LLC bought a new stake in Achaogen in the 2nd quarter valued at approximately $295,000. Institutional investors and hedge funds own 85.74% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/0-79-eps-expected-for-achaogen-inc-akao-this-quarter/1816956.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.